Interim Consolidated Statement of Cash Flows (Unaudited) (USD $) In Millions	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash Flows from Operating Activities
Net income	$ 3,125	$ 1,110
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,663	3,635
Intangible asset impairment charges	439	27
Equity income from affiliates	(193)	(180)
Dividends and distributions from equity affiliates	121	182
Gain on AstraZeneca asset option exercise	0	(443)
Deferred income taxes	(841)	(319)
Share-based compensation	200	274
Other	(456)	410
Net changes in assets and liabilities	(1,485)	(5)
Net Cash Provided by Operating Activities	4,573	4,691
Cash Flows from Investing Activities
Capital expenditures	(689)	(680)
Purchases of securities and other investments	(3,066)	(4,235)
Proceeds from sales of securities and other investments	2,890	1,700
Dispositions of businesses, net of cash divested	323
Acquisitions of businesses, net of cash acquired	(373)	(141)
Proceeds from AstraZeneca option exercise		647
Other	(28)	25
Net Cash Used in Investing Activities	(943)	(2,684)
Cash Flows from Financing Activities
Net change in short-term borrowings	1,396	1,658
Payments on debt	(1,265)	(626)
Purchases of treasury stock	(314)	(1,297)
Dividends paid to stockholders	(2,351)	(2,378)
Proceeds from exercise of stock options	162	237
Other	(57)	(115)
Net Cash Used in Financing Activities	(2,429)	(2,521)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	241	(131)
Net Increase (Decrease) in Cash and Cash Equivalents	1,442	(645)
Cash and Cash Equivalents at Beginning of Year	10,900	9,311
Cash and Cash Equivalents at End of Period	$ 12,342	$ 8,666